Pharmafile Logo

Eureka Therapeutics

- PMLiVE

Promising new agents for multiple myeloma

Drug development for this type of bone marrow cancer has been gaining momentum, with two new proteasome inhibitor approvals in the last year alone and a number of new treatments...

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Sanofi supports Clexane with Spanish VTE apps

The free iPhone, iPad and Android apps are for healthcare professionals

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

Sanofi reception

Sanofi to act as contract manufacturer for Transgene

French biopharma partners with its big pharma compatriot on long-term deal

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Sanofi gets EMA backing for multi-disease vaccine in children

Hexyon-Hexacima 6-in-1 paediatric vaccine recommended for approval in Europe

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links